SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (34789)6/3/2010 5:01:39 PM
From: DewDiligence_on_SI  Respond to of 52153
 
>Bottom line is that reversal of LMWH [by PMX-60056] is not quite as easy as for unfractionated heparin, but if the safety holds up it looks like it would be relatively easily accomplished with the Polymedix drug. Either a longer infusion or multiple doses would be needed if bleeding didn't stop immediately.<

The cumbersome Lovenox-reversal process for PMX-60056 is a boost, albeit a minor one, for MNTA’s M118.



To: Biomaven who wrote (34789)6/3/2010 7:48:34 PM
From: keokalani'nui  Respond to of 52153
 
Thank you very much. Sensible answer and the charts were there after all.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News